Emergent BioSolutions initiates Phase 2 study to evaluate BioThrax Emergent BioSolutions announced the initiation of a Phase 2 study designed to evaluate non-interference of BioThrax when administered in conjunction with antibiotics. This non-interference study will be used to support a supplemental Biologics License Application seeking licensure of a Post-Exposure Prophylaxis indication for BioThrax to be used in combination with antibiotics in people suspected to have been exposed to anthrax spores. The primary objective of this Phase 2 study is to evaluate any impact of the vaccine on ciprofloxacin by administering the antibiotic prior to and following the administration of a 3-dose series of BioThrax. Preliminary data from this study are expected in the fourth quarter of 2013.
Emergent BioSolutions task order shows capabilities, says Summer Street Summer Street says the task order from the U.S. government regarding the manufacturing of ZMapp for treating Ebola shows Emergent BioSolutions' manufacturing capabilities and its working relationship with the government. The firm estimates the contract could be in the multi-$100M range and come as early as Q4, but admits it does not know who will win it. Summer Street views Emergent as undervalued and reiterates a Buy rating on the name with a $35 price target.